ArticleFrontiers in medicine2025

Exploring the binding sites of VRT534 at Cx26 as a putative chemical chaperone for targeted treatment of hereditary hearing disorders.

Jennifer Harre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.